Cargando…
Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
Cutaneous squamous cell carcinoma (cSCC) accounts for 20% of skin cancers. At an advanced stage the prognosis is poor, making cSCC the second leading cause of death from skin cancer. In cases of metastatic or unresectable disease, anti-programmed cell death 1 (anti-PD1) treatment has shown promising...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170330/ https://www.ncbi.nlm.nih.gov/pubmed/34104225 http://dx.doi.org/10.1177/17588359211015493 |